Port Erin Biopharma Investments Ltd PEBI

Last Price
7.13
Day Change
0.13|1.79%

As of 22/05/2013
16:29:54 BST | GBX  Minimum 15 Minutes Delay.

Bid/OfferDay RangeVolume90d Ave VolMkt Cap
0.00 - 0.006.75 - 7.25165,500- 2.411
Last Close52 Week RangeP/EYield %ISIN
7.004.50 - 8.754.210.00IM00B6QH1J21

Port Erin Biopharma Investments Ltd Share Price

Total Returns

 Chg (%)  
3yr, 5yr & 10yr performance data is annualised.
Port Erin Biopharma Investments Ltd-8.06 
FTSE 100 TR GBP3.91
 
Financials
Annual
201020112012
more...
Income Statement
Turnover--0.00
Operating Profit--0.40
Net Profit--0.40
Reported EPS--1.69
Balance Sheet
Current Assets--3.16
Non Current Assets--0.00
Total Assets--3.16
Current Liabilities--0.03
Total Liabilities--0.03
Total Equity--3.12
Cash Flow
Cash From Operations---0.05
Change in Net Cash--0.22
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
more...
'Broker Forecasts' provides consensus figures based on several brokers' views
-------
-------

Regulatory News

Director Dealings
TradedActionNotifierPriceAmountValue
more...
09/04/2013PurchaseJim Mellon7.502,000,000150,000.00
08/04/2013PurchaseJim Mellon7.50200,00015,000.00
06/02/2013PurchaseJim Mellon8.23744,00061,231.00
29/01/2013PurchaseJim Mellon6.26575,00035,995.00

Company Profile

Port Erin Biopharma Investments Ltd invests in biopharmaceutical sector. Its strategy is to create value for Shareholders through investing in companies that have potential to generate substantial revenues through development of biopharmaceutical drugs.

Sector

Healthcare

Industry

Biotechnology

Fiscal Year Ends

June

Employees

-

Outlook

(28/03/2013) ch - "I remain very optimistic about the prospects for our business"

Next Event 30/05/2013

Next AGM
Ratios
 CompSecMkt
PER (E)-13.5213.95
Div Yld (E)-4.763.75
PEG (E)--0.370.24
ROCE12.7351.373.67
Op Mrgn-20.239.06
EPS Grwth-14.6716.04

Broker Forecasts

Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
more...
Directors
more...
ChairmanJim Mellon
Finance DirectorDenham Eke